Dow Weighs Exit From Strained Sadara Chemicals Venture

Dow’s Saudi chemicals venture has become a balance-sheet problem before it became an exit opportunity.

The company is exploring a sale of its 35% stake in Sadara Chemical Company, the $20 billion joint venture formed with Saudi Aramco, according to a Bloomberg report published September 9. No transaction has been agreed, and Aramco or another investor could emerge as the buyer.

Sadara operates a 26-plant complex in Jubail with annual capacity exceeding 3 million metric tons of chemicals and plastics. The project was designed to turn Saudi Arabia’s hydrocarbon advantage into higher-value industrial products, while giving Dow a large, integrated production base in the Gulf.

That industrial logic has not translated into attractive financial returns. Dow reported a negative Sadara investment balance of $793 million at June 30, down from $901 million at the end of 2025, and stopped recognizing its share of the venture’s equity losses during the first quarter because its recorded obligations had reached the level of its commitments.

The pressure is not limited to accounting. Dow said it had guaranteed roughly $1.2 billion of Sadara project-financing principal and related interest. The venture drew $80 million from a revolving credit facility in 2025, and Dow paid that guarantee obligation after the facility expired in the second quarter of 2026. Dow also issued an $86 million letter of credit that expires in the fourth quarter.

Chief Executive Jim Fitterling said in March that Sadara was a low-cash-cost asset operationally, but that fixed costs and financing were creating the strain. Dow’s goal, he said, was to avoid putting additional cash into the venture during 2026.

An exit would give Dow a cleaner path to reduce contingent liabilities and concentrate capital on businesses with stronger returns. It could also help management defend cash flow as the company prioritizes debt reduction and cost savings.

The tradeoff is stark. Sadara remains a strategically important facility with Saudi feedstock access and significant downstream capacity. Selling into a weak global chemicals market might force Dow to accept limited value, or even financial concessions, for a project that could look far more attractive if margins recover.

For investors, the question is less whether Sadara is large than whether it can stop consuming capital. Dow’s review suggests management is no longer willing to pay indefinitely for the venture’s future potential.